0.00 20.00
Prev Close 0.00
Open 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Volume 2.00K
Exchange OTC
Shares Outstanding 42.98M
Market Cap 43.00K
Div & Yield N.A. (N.A)

Don't Get Burned by the Next Cell Genesys

Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.

Feuerstein's Biotech-Stock Mailbag

Cell Genesys' 'news' this week doesn't do much to boost prospects for its prostate cancer vaccine.

Feuerstein's Biotech-Stock Mailbag

Medarex's recent drop in stock price means the FDA isn't likely to approve its melanoma drug soon.

Thursday's Late Winners & Losers

Chordiant inks a big deal with a telecom company.

Top Rocket Stocks for Week of Dec. 24

ValueClick and NetSuite could move higher.

Biotech Notebook: Genitope, Amicus

Failing a phase III trial is never a good thing. Don't believe a CEO's attempt to spin it otherwise.

Thursday's Late Winners & Losers

RIMM benefited from the explosive demand for Blackberry's.

Genitope's MyVax Vaccine Falls Short

The stock gets crushed after the drug can't meet its endpoint.

Feuerstein's Biotech-Stock Mailbag

It's still too early to be a Pain Therapeutics bull.

Genitope Poised for Huge Swing

Study results expected in December offer a big risk/reward scenario.

These 10 Biotechs Have Drugs Near Finish Line

Here's a list of stocks set to report phase III trial results.

Feuerstein's Biotech-Stock Mailbag

This week, questions on Genitope, Immunogen and Nymox. Plus, is Adam really that negative?

Genitope Hammered on Study Setback

The biotech outfit loses nearly half its market cap after saying a trial of MyVax might run until December 2007.

Tuesday's Health Winners & Losers

Hologic moves higher after raising sales projections for its digital-mammography systems.

Andrx Is Anything but Generic

The drugmaker has uncommonly strong finances for a biotech company and trades at a discount.

Go for Value in 2006

S&P 500 companies are flush with cash, as are LBO firms, and they're going to put their money to work.

Be Like Lance When Tracking Stocks

Stamina is key to consistent results, so new traders, lose that rigid, time-consuming routine.

Genitope Holders Bug Out

The shares are down nearly 30% after a data board recommends continuing a lymphoma trial.

A Guide for Genitope Shareholders

The company's waiting on a response from one board before taking its cancer vaccine to the FDA. Here's one analyst's guide.

Dutch Auctions and Their Fans

The aftermarket success of Dutch auction IPOs underscores the value of the process to the Googles and micro-caps of the world.

Here's the Straight Dope on Genitope

The selling in this name has been largely irrational. Cooler heads say it's time to buy.

Venture-backed IPOs Pick Up

Fourth quarter set to be most active in a year but flood of biotech issues brings weak results.